Value-Based Care

Amitkumar Mehta, MD, MBA, University of Alabama at Birmingham, notes the long-term data and potential curative effects of chimeric antigen receptor (CAR) T-cell therapy, while expressing optimism about bispecific therapy with ongoing evolution and the chance of significant patient responses.

Edward "Ted" Arrowsmith, MD, MPH, medical director for pathways at OneOncology and managing partner at Tennessee Oncology, highlights the need for trust between payers and providers, as well as finding balance in building consistent clinical pathways while prioritizing specific practice needs.

Investigators propose potential payment models for gene therapies that consider equitable patient access and payer reimbursement.

There is a lot of noise in the health care system, and oncologists need to collaborate and decide on common shared goals, said Lucy Langer, MD, MSHS, national medical director of oncology and genomics at UnitedHealthcare.

Leveraging technology intelligently can make the patient-doctor interaction much more seamless and connected, said Samyukta Mullangi, MD, MBA, medical director of oncology at Thyme Care, medical oncologist at Tennessee Oncology.

This 2022 survey of Medicare accountable care organizations (ACOs) shows significant growth in non-Medicare value-based contracts and in contracts with downside risk.

The Enhancing Oncology Model is trying to address a number of the systemic challenges oncology faces without giving practices the tools and resources they need, said Nicolas Ferreyros, managing director of policy, advocacy, and communications, Community Oncology Alliance.

Sophia Humphreys, PharmD, MHA, BCBBS, discusses highlights of the Institute for Value-Based Medicine® (IVBM) event, held in partnership with Providence Health System, that recently took place in Newport Beach, California.

Federal actuaries have projected what they believe to be health care spending through 2030-2031 in 9 important areas.

Through the integration of a population health reimbursement model in 2020, Allina Health Cancer Institute was able to implement expanded screening initiatives through the use of artificial intelligence and precision medicine, according to Mike Koroscik, MBA, MHA, vice president of oncology, Allina Health.

Melissa Levine, MD, a family medicine specialist at Arizona Community Physicians and medical director for the Abacus Health accountable care organization (ACO), discussed strategies for succeeding in an ACO and how primary care can complement oncology care for patients with cancer.

At the 2023 COA Payer Exchange Summit being held October 23-24 in Reston, Virginia, Lalan Wilfong, MD, US Oncology Network, emphasizes the importance of oncology care equity, ensuring continuity of care, and enhancing care coordination.

This analysis demonstrates value and innovation of direct-acting antivirals for the treatment of chronic hepatitis C in the US Kaiser Permanente health system.

Sarah Boyce, president and CEO at Avidity Biosciences, discusses her leading role at the company, as well as antibody oligonucleotide conjugate drug, AOC 1044, currently in development for Duchenne muscular dystrophy (DMD) with mutations amenable to exon 44 skipping (DMD44).

A presentation at the Association of Community Cancer Centers’ 40th National Oncology Conference explored how a cancer screening initiative can be sustainable and revenue positive while driving value-based savings in an evolving market.

Olalekan Ajayi, PharmD, MBA, 2023-2024 president of the Association of Community Cancer Centers (ACCC) and chief operating officer of Highlands Oncology Group, PA, reflects upon his role at ACCC and highlights key topics in oncology care and cancer research that will be presented at the National Oncology Conference.

This year’s 40th National Oncology Conference from the Association of Community Cancer Centers (ACCC) will take place in Austin, Texas, from October 4-6, with content designed to reflect the theme of “Reimagining Innovation.”

Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.

Jennifer Sturgill, DO, inpatient medical director of population health, Central Ohio Primary Care, co-presented “Value-Based Care: What Is It and Why Should We Care?” at our most recent Institute for Value-Based Medicine® event with the Zangmeister Cancer Center of Columbus, Ohio, on September 14.

Kristin Oaks, DO, Agilon regional medical director at Central Ohio Primary Care, spoke at our recent Institute for Value-Based Medicine® event held with Zangmeister Cancer Center. Here, she addresses the importance of value-based care within the primary care space.

Most people don’t know they have hypertension, and a new recommendation advises that pregnant women should be screened for blood pressure disorders at every appointment; patients in primary care face long wait times, which may be due to physician incentives under value-based payments; a lawsuit in New Jersey targets the residency requirement to allow aid in dying for those out of state.

We are in the midst of a transformative time in oncology that could also be a little scary if you are not prepared, said Nicolas Ferreyros, managing director of policy, advocacy, and communications, Community Oncology Alliance.

During this session at the National Comprehensive Cancer Network (NCCN) Policy Summit, Yelak Biru, MSc, and Crystal S. Denlinger, MD, explained the importance of screening for and addressing health-related social needs.

In this interview from our Institute for Value-Based Medicine® event, held in partnership with the Zangmeister Cancer Center of Columbus, Ohio, on September 14, Kristine Slam, MD, FACP, Central Ohio Surgical Associates, discusses the benefits of value-based care in the breast cancer space.

Specialty pharmacy is a big area of growth, with opportunity for patients, and specialty pharmacists can help payers and insurers ensure that patients get the full value of oncology medications, noted Andre Harvin, PharmD, MS, MBA, chief pharmacy officer, Oncology Services, Cone Health Cancer Centers.